Ríhová Blanka, Kovár Lubomír, Kovár Marek, Hovorka Ondrej
Institute of Microbiology Academy of Sciences of the Czech Republic, v.v.i., Videnska 1083, 142 20 Prague 4, Czech Republic.
Trends Biotechnol. 2009 Jan;27(1):11-7. doi: 10.1016/j.tibtech.2008.10.006. Epub 2008 Nov 18.
The successful treatment of cancer with conventional drugs is frequently complicated by the resistance of tumor cells to such a non-specific therapy. Over the last few years, immunotherapy has gained attention as a tumor-specific approach. Recent findings demonstrated that some conventional cytostatics stimulate local anticancer responses. New anticancer drugs, including their polymeric derivatives, are currently being developed with the aim of destroying tumors more effectively and more specifically. Among these, the water-soluble conjugates of doxorubicin with N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer carrier have emerged as efficient therapeutics because they are able to not only directly destroy cancer cells but also elicit systemic tumor-specific anticancer responses. Here, we discuss new insights into their mechanisms of immune surveillance, which could suggest novel approaches to cancer therapy.
传统药物对癌症的成功治疗常常因肿瘤细胞对这种非特异性疗法产生耐药性而变得复杂。在过去几年中,免疫疗法作为一种肿瘤特异性方法受到了关注。最近的研究结果表明,一些传统的细胞抑制剂可刺激局部抗癌反应。目前正在研发包括其聚合物衍生物在内的新型抗癌药物,旨在更有效、更特异性地摧毁肿瘤。其中,阿霉素与N-(2-羟丙基)甲基丙烯酰胺(HPMA)共聚物载体的水溶性缀合物已成为有效的治疗药物,因为它们不仅能够直接摧毁癌细胞,还能引发全身性肿瘤特异性抗癌反应。在此,我们讨论对其免疫监视机制的新见解,这可能为癌症治疗提供新方法。